Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of OncoSorb® in Patients With Advanced Cancer Entities

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with metastatic solid cancer who have documented progressive disease and who have failed standard therapy~* Measurable disease (RECIST criteria)~* Expected survival of at least 4 months~* Performance status ECOG 0 and 1~* Vital laboratory parameters within normal range, or protocol specified ranges~* Able to give written informed consent~* The patient's sTNF-R1, sTNF-R2 levels in citrate plasma are \> 500 pg/ml and \> 1000 pg/ml respectively~* The patient has adequate renal function as evidenced by glomerular filtration rate \> 80 ml/min~* Patient 5 with metastatic melanoma must have skin lesion(s)~* Patient 5 with metastatic melanoma should have slow tumor progression~* Patient 5 with metastatic melanoma must have an intact TNF-receptor signaling cascade, resulting in measurable induction of cancer cell apoptosis following the exposition to TNF-α in vitro. This will be evidenced by destruction of primary autologous cancer cells obtained by biopsy.~Exclusion Criteria:~* Other serious or significant illnesses~* Other malignancy within the last 3 years, except for target oncological indication (does not exclude metastatic sites)~* Known immunodeficiency~* Known HIV or hepatitis positivity~* Using systemic immunosuppressive drugs. (Exceptions: Specific COX-2 inhibitors; low dose aspirin for cardiovascular event prevention; topical/inhaled steroids)~* Chemotherapy, immunotherapy or radiotherapy within two weeks prior to start of OncoSorb® treatments provided that all prior therapy related toxicities are resolved~* Participation in a prior clinical trial involving an investigational agent within the last 2 weeks~* Not available for clinical follow-up assessments~* Pregnancy or breastfeeding~* Refusal or inability to use effective means of contraception for women of childbearing potential~* Mental impairment that may compromise ability to give informed consent and to comply with study requirements~* History of a myocardial infarction within 6 months prior to the start of study, uncontrolled congestive heart failure, or any current Grade 3 or 4 cardiovascular disorder despite treatment~* Coagulation disorders and / or a history of thromboembolic complications~* Any significant disease that, in the Investigator's opinion, should exclude the patient from the study~* Known hypersensitivity or allergy to rabbit proteins~* Known hypersensitivity to heparin or citrate~* The patient receives Angiotensin-Converting Enzyme (ACE) inhibitors or Coumadin (Marcumar®) as concomitant medication~* Patient 5 with metastatic melanoma with brain metastases (MRT scan)~* Patient 5 with metastatic melanoma is severely immunocompromised (patient must have average or low TREG counts, no dysfunctional T cells like e.g. CD28-)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OncoSorb® column (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy